KBC Group
MRNS

KBC Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

KBC Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,600
Closed -$13K – 1329
2020
Q1 		$13K Hold
1,600
– – ﹤0.01% 1265
2019
Q4 		$14K Buy
1,600
+1,292
+419% +$7.25K ﹤0.01% 1475
2019
Q3 		$2K Sell
308
-1,255
-80% -$10.1K ﹤0.01% 1473
2019
Q2 		$26K Hold
1,563
– – ﹤0.01% 1402
2019
Q1 		$26K Buy
1,563
+500
+47% +$7.2K ﹤0.01% 1364
2018
Q4 		$12K Sell
1,063
-900
-46% -$18.2K ﹤0.01% 1288
2018
Q3 		$79K Hold
1,963
– – ﹤0.01% 1307
2018
Q2 		$56K Hold
1,963
– – ﹤0.01% 1218
2018
Q1 		$30K Buy
+1,963
New +$46.7K ﹤0.01% 1240

Other funds holding MRNS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

KBC Group's MRNS Position: Q2 2020 in Review

KBC Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2020, closing a stake of 1,600 shares — an estimated $13K sold.

KBC Group first reported a position in MRNS in Q1 2018 and held it in 9 quarters. The position peaked at $79K in Q3 2018. 94 funds tracked by Wall St. Rank hold MRNS as of Q2 2020.

  • KBC Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
  • KBC Group sold 1,600 Marinus Pharmaceuticals, Inc shares in Q2 2020, an estimated $13K.
  • KBC Group first reported a position in Marinus Pharmaceuticals, Inc in Q1 2018 and held it in 9 quarters.
  • KBC Group's Marinus Pharmaceuticals, Inc position peaked at $79K in Q3 2018.
  • 94 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2020.

Based on KBC Group's 13F filing for Q2 2020, filed 10 Aug 2020.